VILNIUS, Lithuania, July 27, 2024 /PRNewswire/ -- BingX, a leading cryptocurrency exchange, proudly announces the launch of BingX Pre-Market Trading feature. Utilizing this feature, BingX users can enjoy early access to coins, efficient price discovery, and enhanced liquidity. It also allows for the activation of community trading interests, positioning BingX as a primary market for new assets once they are officially listed. This innovative platform enhancement is set to redefine the landscape of cryptocurrency trading, providing users with unprecedented early access to new digital assets before their official listing, starting with Hamster Kombat (HMSTR) and Catizen (CATI). This captivating clicker game has garnered a substantial user base interested in the TON Ecosystem built on the Telegram instant messaging app.
Vivien Lin, Chief Product Officer of BingX, expressed her enthusiasm and emphasized the feature's significance for the platform's users. "This new feature represents a major milestone for BingX, providing our users with early access to new coins and the ability to secure advantageous positions before these coins are listed on the spot market. We are dedicated to continually innovating and delivering tools that empower our users to stay ahead in the dynamic cryptocurrency market." said Lin.
Early Opportunities & Real Trades
BingX Pre-Market Trading operates as an over-the-counter (OTC) platform, facilitating genuine peer-to-peer trading of new coins. This feature allows users to acquire coins at optimal prices, secure liquidity in advance, and complete deliveries at mutually agreed-upon times. allowing buyers and sellers to freely choose and create orders based on their preferences and price expectations. Whether acting as a buyer, seller, or both, users can set their desired prices and quantities, ensuring a flexible and user-driven trading environment.
The platform ensures transaction security by freezing the relevant amounts for both buyers and sellers, guaranteeing that every order has solid financial backing. This reduces the risk of failed trades. Sellers can also complete deliveries as soon as they have the coins, locking in their order profits without waiting for the delivery period to end. As a trusted leader in the cryptocurrency trading industry, BingX continues to innovate and deliver features that enhance the trading experience for its global user base. The launch of the Pre-Market Trading feature highlights BingX's commitment to security, reliability, and user empowerment.
About BingX
Founded in 2018, BingX is a leading crypto exchange, serving over 10 million users worldwide. BingX offers diversified products and services, including spot, derivatives, copy trading, and asset management – all designed for the evolving needs of users, from beginners to professionals. BingX is committed to providing a trustworthy platform that empowers users with innovative tools and features to elevate their trading proficiency. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports.
For more information please visit: https://bingx.com/en/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
BingX Launches Pre-Market Trading for Early Access to New Digital Assets
First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research
FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanced panel now features brain-derived pTau217, pTau181, pTau231, and total tau (tTau) protein measured directly from blood samples—delivering unprecedented sensitivity and specificity for the study of neurodegenerative diseases.
Phosphorylated tau has emerged as a critical biomarker for early detection and monitoring of Alzheimer's disease and other tauopathies. The new additions to the CNS Disease 120 Panel are specifically designed to detect brain-derived forms of pTau, overcoming the limitations of current assays that cannot distinguish between peripheral and central tau species. This allows for the simultaneous measurement of two suites of multiple pTaus and tTau species, one specific for brain-derived and one combining brain- and peripheral tissue-derived Tau species.
"Researchers have long sought a reliable, blood-based solution to track brain-derived tau pathology," said Dr. Yuling Luo, CEO, Founder and Chairman of Alamar Biosciences. "By integrating assays for pTau217, pTau181, pTau231, and total tau into our NULISAseq CNS Disease 120 Panel, we are enabling scientists to explore the full spectrum of tau pathology with exceptional sensitivity and throughput. This advancement is poised to accelerate biomarker-driven research and drug development in Alzheimer's Disease and related neurodegenerative disorders."
"The ability to detect brain-derived pTau species directly from blood represents a transformative step in the early detection and monitoring of Alzheimer's Disease (AD) and related disorders," said Nicholas Ashton, Ph.D., Director of Neurodegenerative Biomarker Research at Banner Health. "Until now, we've been unable to differentiate between brain-derived and peripheral pTaus in a multiplexed manner. Recent evidence has underlined the importance of being able to detect brain-derived pTau for greater specificity for AD. Alamar's new CNS panel offers an unprecedented opportunity to further improve the diagnostic accuracy and clinical utilities of these biomarkers, which will dramatically impact patient care and clinical research."
Alamar Biosciences remains committed to partnering with the neuroscience community to unlock biomarker insights that drive earlier diagnosis, patient stratification, and therapeutic monitoring.
For more information about the NULISAseq CNS Disease Panel 120 and Alamar Biosciences' portfolio of proteomic solutions, visit www.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGOâ„¢ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
